Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy

Cancer Immun. 2010 Jan 7:10:1.

Abstract

Melanoma patients treated with anti-CTLA-4 have shown a range of anti-tumor responses. In this report, we describe the response of a single patient to anti-CTLA-4, with individual lesions disappearing, others stabilizing, and others progressing. These responses can be viewed as a clear manifestation of cancer immunoediting and its three phases of elimination, equilibrium and escape, with each tumor in this patient being at a discrete stage in the process. The patient's course and associated immunological monitoring and other laboratory data are presented in an immunogram, a way to visualize temporal associations between the multiple clinical and laboratory parameters.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Cell Count
  • Cell Separation
  • Female
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • Ipilimumab
  • Lymphocytes / drug effects
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / secondary*
  • Middle Aged
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Ipilimumab